101 related articles for article (PubMed ID: 10480630)
1. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.
Haslett PA; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1169-79. PubMed ID: 10480630
[TBL] [Abstract][Full Text] [Related]
2. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
Hengge UR; Goos M; Esser S; Exner V; Dötterer H; Wiehler H; Borchard C; Müller K; Beckmann A; Eppner MT; Berger A; Fiedler M
AIDS; 1998 Dec; 12(17):F225-34. PubMed ID: 9863864
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis.
Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G
J Infect Dis; 2000 Mar; 181(3):954-65. PubMed ID: 10720518
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
6. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
7. The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children.
Hanekom WA; Hughes J; Haslett PA; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G
J Infect Dis; 2001 Nov; 184(9):1192-6. PubMed ID: 11598844
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety.
Vergara TRC; Samer S; Santos-Oliveira JR; Giron LB; Arif MS; Silva-Freitas ML; Cherman LA; Treitsman MS; Chebabo A; Sucupira MCA; Da-Cruz AM; Diaz RS;
EBioMedicine; 2017 Sep; 23():59-67. PubMed ID: 28822719
[TBL] [Abstract][Full Text] [Related]
10. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection.
Malhotra U; Berrey MM; Huang Y; Markee J; Brown DJ; Ap S; Musey L; Schacker T; Corey L; McElrath MJ
J Infect Dis; 2000 Jan; 181(1):121-31. PubMed ID: 10608758
[TBL] [Abstract][Full Text] [Related]
11. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
12. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
[TBL] [Abstract][Full Text] [Related]
13. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
[TBL] [Abstract][Full Text] [Related]
14. Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.
Levacher M; Bouscarat F; Landman R; Chau F; Damond F; Gaudebout C; Mathez D; Leibowitch J; Saimot AG; Sinet M
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1869-75. PubMed ID: 11118072
[TBL] [Abstract][Full Text] [Related]
15. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
16. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
[TBL] [Abstract][Full Text] [Related]
17. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
[TBL] [Abstract][Full Text] [Related]
18. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
[TBL] [Abstract][Full Text] [Related]
20. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
Gartland M;
Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
